The Benefits and Side Effects of Bevacizumab for the Treatment of Recurrent Ovarian Cancer

E-ISSN： 1873-5592|18|10|1125-1131

ISSN： 1389-4501

Source： Current Drug Targets, Vol.18, Iss.10, 2017-07, pp. : 1125-1131

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Bevacizumab costly for ovarian cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 624, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Bevacizumab in Ovarian Cancer: Unanswered Questions

By Muggia Franco

Drugs, Vol. 72, Iss. 7, 2012-05 ,pp. : 931-936

Adis International

Access to resources Recommend Favorite

Bevacizumab Combination Therapy: For the First-Line Treatment of Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

By Dhillon Sohita

Drugs, Vol. 72, Iss. 7, 2012-05 ,pp. : 917-930

Adis International

Access to resources Recommend Favorite

The Role of Bevacizumab in Advanced Epithelial Ovarian Cancer

Current Pharmaceutical Design, Vol. 18, Iss. 25, 2012-07 ,pp. : 3775-3783

Bentham Science Publishers

Access to resources Recommend Favorite

Current treatment for ovarian cancer

By Eltabbakh G.H. Awtrey C.S.

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 1, 2001-01 ,pp. : 109-124

Informa Healthcare

Access to resources Recommend Favorite